Skip to Content

Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in Breast Cancer Patients Previously Treated with Endocrine Therapy

A new study presented at the 2024 ASCO Annual Meeting shows that trastuzumab deruxtecan outperforms standard chemotherapy in delaying cancer progression for HR+, HER2-low, and HER2-ultralow metastatic breast cancer patients.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top